Fig. 3
From: SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
SMARCA4/2 loss causes reduced cyclin D1 expression in non-small cell lung cancer (NSCLC). a–d SMARCA4/2 regulate cyclin D1 expression in NSCLC. a, b SMARCA4 restoration upregulates cyclin D1 protein (left) and messenger RNA (mRNA) (right) expression in H1299 (a) and H1703 (b) cells. c SMARCA2 knockdown in H1299 cells suppresses cyclin D1 protein (left) and mRNA (right) expression. d SMARCA2 restoration in H1703 cells elevates cyclin D1 protein (left) and mRNA (right) expression. Relative CCND1 mRNA expression (relative to GAPDH) was measured by real-time quantitative reverse transcription PCR (RT-qPCR). Error bars: mean ± s.d. of biological replicates (n = 3, two-tailed t-test, *p < 0.05, **p < 0.01, ***p < 0.001). e, f Correlation of CCND1 and SMARCA4 mRNA expression in two cohorts of lung adenocarcinomas (LUADs) from BC Cancer Agency (BCCA; n = 83, e) and The Cancer Genome Atlas (TCGA; n = 230, f). g Correlation of CCND1 and SMARCA2 mRNA expression in SMARCA4-mutated LUADs (n = 13) in the TCGA cohort. r, Pearson's correlation coefficient. h–j Immunohistochemistry (IHC) analysis of cyclin D1 protein expression in two cohorts of NSCLC patient tumors: NCT (n = 93; h, i) and McGill University Health Center (MUHC; n = 91; j). Representative IHC images of SMARCA4 IHC-negative tumors are shown; a SMARCA4/2 IHC-positive tumor served as staining control (h). Cyclin D1 in IHC analysis was quantified with H-score and analyzed by Wilcoxon rank sum test (i, j)
